246 related articles for article (PubMed ID: 18171013)
1. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability.
Dhanikula RS; Argaw A; Bouchard JF; Hildgen P
Mol Pharm; 2008; 5(1):105-16. PubMed ID: 18171013
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
3. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.
Ying X; Wen H; Lu WL; Du J; Guo J; Tian W; Men Y; Zhang Y; Li RJ; Yang TY; Shang DW; Lou JN; Zhang LR; Zhang Q
J Control Release; 2010 Jan; 141(2):183-92. PubMed ID: 19799948
[TBL] [Abstract][Full Text] [Related]
4. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.
Li Y; He H; Jia X; Lu WL; Lou J; Wei Y
Biomaterials; 2012 May; 33(15):3899-908. PubMed ID: 22364698
[TBL] [Abstract][Full Text] [Related]
5. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma.
Xin H; Jiang X; Gu J; Sha X; Chen L; Law K; Chen Y; Wang X; Jiang Y; Fang X
Biomaterials; 2011 Jun; 32(18):4293-305. PubMed ID: 21427009
[TBL] [Abstract][Full Text] [Related]
6. Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate.
Dhanikula RS; Hildgen P
Biomaterials; 2007 Jul; 28(20):3140-52. PubMed ID: 17428531
[TBL] [Abstract][Full Text] [Related]
7. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
9. On the mechanism and dynamics of uptake and permeation of polyether-copolyester dendrimers across an in vitro blood-brain barrier model.
Dhanikula RS; Hammady T; Hildgen P
J Pharm Sci; 2009 Oct; 98(10):3748-60. PubMed ID: 19156840
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of the effectiveness of poly(ε-caprolactone) lipid-core nanocapsules loaded with methotrexate on glioblastoma multiforme treatment.
Pereira NRC; Loiola RA; Rodrigues SF; de Oliveira CP; Büttenbender SL; Guterres SS; Pohlmann AR; Farsky SH
Int J Nanomedicine; 2018; 13():4563-4573. PubMed ID: 30154652
[TBL] [Abstract][Full Text] [Related]
11. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide.
Lindgren M; Rosenthal-Aizman K; Saar K; Eiríksdóttir E; Jiang Y; Sassian M; Ostlund P; Hällbrink M; Langel U
Biochem Pharmacol; 2006 Feb; 71(4):416-25. PubMed ID: 16376307
[TBL] [Abstract][Full Text] [Related]
12. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors.
He H; Li Y; Jia XR; Du J; Ying X; Lu WL; Lou JN; Wei Y
Biomaterials; 2011 Jan; 32(2):478-87. PubMed ID: 20934215
[TBL] [Abstract][Full Text] [Related]
13. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
14. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.
Yuan SH; Ge WH; Huo J; Wang XH
Fundam Clin Pharmacol; 2009 Apr; 23(2):189-96. PubMed ID: 19298236
[TBL] [Abstract][Full Text] [Related]
15. [Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
Chen J; Gu LJ; Ying DM; Shen M; Wu HJ
Ai Zheng; 2002 Dec; 21(12):1335-40. PubMed ID: 12520743
[TBL] [Abstract][Full Text] [Related]
16. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585
[TBL] [Abstract][Full Text] [Related]
17. Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma.
Xue H; Wang H; Kong L; Zhou H
Chin Med J (Engl); 1998 Aug; 111(8):751-3. PubMed ID: 11245034
[TBL] [Abstract][Full Text] [Related]
18. Liposomes containing alkylated methotrexate analogues for phospholipase A(2) mediated tumor targeted drug delivery.
Kaasgaard T; Andresen TL; Jensen SS; Holte RO; Jensen LT; Jørgensen K
Chem Phys Lipids; 2009 Feb; 157(2):94-103. PubMed ID: 19094974
[TBL] [Abstract][Full Text] [Related]
19. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
[TBL] [Abstract][Full Text] [Related]
20. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors.
Gilg AG; Tye SL; Tolliver LB; Wheeler WG; Visconti RP; Duncan JD; Kostova FV; Bolds LN; Toole BP; Maria BL
Clin Cancer Res; 2008 Mar; 14(6):1804-13. PubMed ID: 18347183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
